Semin Respir Crit Care Med 2020; 41(01): 003-012
DOI: 10.1055/s-0040-1701215
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Invasive Candidiasis

María F. Gonzalez-Lara
1  Clinical Microbiology Laboratory, Infectious Diseases Department, Instituto Nacional de Ciencias Médica y Nutrición Salvador Zubirán, Mexico City, Mexico
Luis Ostrosky-Zeichner
2  Division of Infectious Diseases, University of Texas Health Medical School, Houston, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
30 January 2020 (online)


Invasive candidiasis (IC) is the most frequent health care associated invasive fungal infection. It is also associated with high morbidity, mortality, and cost. The most frequent etiologic agent is Candida albicans, but non-albicans species are increasing and associated with reduced antifungal susceptibility and outbreaks. Candida auris is an emerging multidrug-resistant species recently described. IC presents as a spectrum of disease, going from fungemia to deep-seated candidiasis, and to septic shock with multiorgan failure. Diagnosis of IC is challenging. Several biomarkers and molecular methods are available for improving diagnosis. Early initial treatment with echinocandins is the treatment of choice. Step-down therapy when antifungal susceptibility is available is possible. Several new antifungal agents for the treatment of IC are in clinical development.


Relevant to this topic, L.O. has received consulting, speaking, or research funding from the following companies: Astellas, Pfizer, Scynexis, Amplyx, Cidara, F2G, Gilead, RealTime, and Viracor. M.F.G.L has received consulting and speaking fees from Pfizer and Grupo Biotoscana.